A Study of JNJ-73763989 in Healthy Chinese Adult Participants

Phase 1 Completed 18 enrolled Janssen Research & Development, LLC

RandomizedParallel-groupOpen-labelOther

Summary

The purpose of the study is to evaluate the single-dose Pharmacokinetics of JNJ-73763976 and JNJ-73763924 following a subcutaneous (SC) injection of JNJ-73763989 (JNJ-3989) in healthy Chinese adult participants at 2 different doses, Dose 1 (Panel A) or Dose 2 (Panel B).

Timeline

Start: 2020-11-24
Primary completion: 2021-02-18
Completion: 2021-02-18

Publications

Li H, Niu X, Zhang Y, Zhang D, Zhang Y, Wang L, Miao Y, Jiang Y, Ji J, Chen Q, Wu X, Ediage EN, Kakuda TN, Biermer M. Pharmacokinetics, Safety, and Tolerability of the siRNA JNJ-73763989 in Healthy Chinese Adult Participants. Clin Pharmacol Drug Dev. 2023 Feb;12(2):175-180. doi: 10.1002/cpdd.1197. Epub 2022 Nov 22.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	JNJ-73763989	Small interfering RNA (siRNA)	100 mg	Subcutaneous
Subject	JNJ-73763989	Small interfering RNA (siRNA)	200 mg	Subcutaneous

Indications

No indication recorded.